Bahrain allows Sinopharm COVID-19 vaccine candidate use in frontline workers
Bahrain has granted emergency approval for the use of a Chinese COVID-19 vaccine candidate currently in phase III trials on frontline workers from Tuesday, state news agency BNA said.
The vaccine candidate, nearing the end of phase III trials in the United Arab Emirates, Egypt, Bahrain and Jordan, is a partnership between Sinopharm’s China National Biotec Group (CNBG) and Abu Dhabi-based artificial intelligence and cloud computing company Group 42 (G42).
The UAE in September authorised similar emergency use of the same vaccine for frontline workers at high risk of infection with the new coronavirus.
Bahrain’s Health Minister Faeqa bint Saeed Al Saleh said on Tuesday, in comments carried by BNA, that the use of the vaccine complies with the country’s regulations on exceptional licensing in emergency cases.
“The results of phase I and phase II clinical trials showed the vaccine is safe and effective,” she said, adding that phase III trials were going smoothly and without serious side effects.
Around 7,770 people have so far volunteered in the phase III trials in Bahrain and have received a second dose, the minister added.
The phase III trials of the inactivated virus vaccine began in mid-July in the UAE, and were expanded to Bahrain, Egypt and Jordan.
G42 Healthcare CEO Ashish Koshy last month said the vaccine had been administered to more than 31,000 people across those countries.
Several ministers and senior officials have already received the vaccine in both the UAE and Bahrain, including Bahrain’s crown prince.
On Tuesday, prime minister and vice-president of the UAE and Ruler of Dubai Sheikh Mohammed bin Rashid al-Maktoum tweeted a picture of him receiving a shot of a COVID-19 vaccine.